The present invention relates to a multicellular construct that includes cells and a scaffold. The scaffold is constituted by a layered composite that comprises a gelatin nonwoven containing gelatin as a main component, and a gelatin film containing gelatin as a main component and layered on one surface of the gelatin nonwoven, and the cells are present in at least one of a region on the surface of the gelatin nonwoven and a region inside the nonwoven. The multicellular construct can be produced by arranging the scaffold in a swollen state inside the culture vessel whose inner surface is in the dry state such that the gelatin film of the scaffold is in contact with the inner bottom surface of the culture vessel, dripping a cell suspension onto the gelatin nonwoven of the scaffold, and then culturing the cells. This makes it possible to provide a multicellular construct with high seeding efficiency in which desorption of cells from a scaffold is suppressed, a method for manufacturing the same, a kit for producing the same, and a method for evaluating a compound using the same.

A method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof is provided. The method comprising administering to the subject a composition comprising a therapeutically effective amount of astrocytes, thereby treating the ARDS.

The present invention provides a new method related to regenerative medicine for the treatment of cartilage disorders, osteoarthritis and cartilage injury in particular. More particularly, it relates to an FGF-18 compound for use in tissue engineering and graft procedures, such as osteochondral or cartilage transplantation or autologous chondrocyte implantation (ACI).

Methods for improved handling of isolated canine umbilical cord mesenchymal stromal cells (UC-MSCs), including methods for expansion of canine UC-MSCs, cryopreservation and improved post-thaw viability using adherent plates, as well as standardized methods and kits for characterizing isolated canine UC-MSCs in a cell population. Methods for improved detachment or dissociation of adherent cells and new dissociation reagents comprising nattokinase are also disclosed.

According to a production method for a brain organoid, comprising a step 1 of carrying out suspension culture of human pluripotent stem cells having a mutation in at least one or more base sequences in an exon selected from the group consisting of an exon 9, an exon 10, an exon 11, an exon 12, and an exon 13 of a microtubule-associated protein tau (MAPT) gene, and having a mutation in at least one or more base sequences in an intron 10 of the MAPT gene, it is possible to produce a brain organoid having a phosphorylated 3-repeat tau protein and a phosphorylated 4-repeat tau protein.

The invention relates to methods for generating multipotent mammary stem cells from isolated and cultured human breast luminal cells. The method comprises the steps: 1. isolating and growing normal differentiated cells in vitro; 2. treating the differentiated cells with either a conditioned medium from active fibroblasts or cytokine. The invention also relates to multipotent mammary stem cells, cultures of the multipotent stem cells, differentiated cells, tissues, organs derived from the culture multipotent stem cells isolated by the methods disclosed and therapeutic and other uses for those cells thereof.

Disclosed herein are methods for generating satellite cells and compositions including satellite cells.

Disclosed herein is a method for covalent immobilization of molecular compounds on a substrate surface, comprising the steps: Providing a substrate surface; Treating the substrate surface with a plasma at atmospheric pressure, thereby generating an activated surface site; Exposing at least the activated surface site, or some fraction of the activated surface site, to molecular compounds, thereby establishing a covalent bond between the molecular compounds and the substrate surface.

Kits for making a spheroid-stabilizing hydrogel in a calcium-free or calcium-chelated cell culture media include (a) a gelation agent including a polygalacturonic acid (PGA) compound or an alginic acid compound, wherein the PGA compound includes at least one of: (i) pectic acid or salts thereof, or (ii) partially esterified pectic acid having a degree of esterification from about 1 to about 40 mol % or salts thereof; (b) a crosslinking agent, wherein the crosslinking agent includes a salt of a divalent ion; and (c) a proton donor, wherein the proton donor includes lactones, esters, or other compounds that hydrolyze in aqueous solutions to form acids over a period of from 10 minutes to 1 hour. Resultant spheroid-stabilizing hydrogels and methods of preparing the same.

This disclosure relates to endothelial and smooth muscle like vascular tissue produced from urine cells. In certain embodiments, the disclosure relates to methods of producing endothelial and smooth muscle like vascular tissue by exposing urine derived cells with ETV2 in a first growth media under conditions such that the cells are modified to form a pool of cells expressing increased levels of endothelium surface markers and thereafter exposing the pool of cells to a second growth media under conditions such that the cells are modified to form tissue containing cells expressing increased levels of smooth muscle surface markers in addition to the endothelium surface markers. In certain embodiments, the disclosure relates to using cells and tissues reported herein for the treatment of vascular, cardiac, and wound healing indications.